Immunic highlights 2024 accomplishments and upcoming milestones

–  top-line data from phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis expected in april – – reported positive outcome from interim analysis of ongoing, twin phase 3 ensure trials of vidofludimus calcium in relapsing multiple sclerosis; both trials on track to be completed in 2026 – – strengthened management team and board of directors with key hires – – announced a three-tranche private placement totaling up to $240 million, extending cash runway into the third quarter of 2025, based on initial $80 million tranche – new york , jan. 7, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2024 accomplishments and upcoming milestones. "the past year was marked by substantial progress for our orally available lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), as we continued to advance both our phase 2 calliper trial in patients with progressive multiple sclerosis (pms) and our twin phase 3 ensure trials in relapsing multiple sclerosis (rms)," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking